The American Heart Journal published an analysis of three research trials using BG Medicine Inc.’s (Nasdaq: BGMD) BGM Galectin-3® Test saying that the test was significantly predictive of rehospitalization for heart failure. The stock price soared 51 cents to $2.21.
BG Medicine’s BGM Galectin-3 Significantly Predictive
March 25, 2014 at 06:39 AM EDT
